Repository logo
 
Publication

Changes in Glycolytic Pathway in SARS-COV 2 Infection and Their Importance in Understanding the Severity of COVID-19

dc.contributor.authorSantos, Adalberto
dc.contributor.authorPóvoa, Pedro
dc.contributor.authorPaixão, Paulo
dc.contributor.authorMendonça, António
dc.contributor.authorBarata, Luís Manuel Taborda
dc.date.accessioned2022-08-23T09:25:17Z
dc.date.available2022-08-23T09:25:17Z
dc.date.issued2021-09-10
dc.description.abstractCOVID-19 is an infectious disease caused by Coronavirus 2 (SARS-CoV-2) that may lead to a severe acute respiratory syndrome. Such syndrome is thought to be related, at least in part, to a dysregulation of the immune system which involves three main components: hyperactivity of the innate immune system; decreased production of type 1 Interferons (IFN) by SARS-CoV-2-infected cells, namely respiratory epithelial cells and macrophages; and decreased numbers of both CD4+ and particularly CD8+ T cells. Herein, we describe how excessive activation of the innate immune system and the need for viral replication in several cells of the infected organism promote significant alterations in cells’ energy metabolism (glucose metabolism), which may underlie the poor prognosis of the disease in severe situations. When activated, cells of the innate immune system reprogram their metabolism, and increase glucose uptake to ensure secretion of proinflammatory cytokines. Changes in glucose metabolism are also observed in pulmonary epithelial cells, contributing to dysregulation of cytokine synthesis and inflammation of the pulmonary epithelium. Controlling hyperglycolysis in critically ill patients may help to reduce the exaggerated production of pro-inflammatory cytokines and optimise the actions of the adaptive immune system. In this review, we suggest that the administration of non-toxic concentrations of 2-deoxy-D-glucose, the use of GLUT 1 inhibitors, of antioxidants such as vitamin C in high doses, as well as the administration of N-acetylcysteine in high doses, may be useful complementary therapeutic strategies for these patients, as suggested by some clinical trials and/ or reports. Overall, understanding changes in the glycolytic pathway associated with COVID-19 infection can help to find new forms of treatment for this disease.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationSantos AF, Póvoa P, Paixão P, Mendonça A and Taborda-Barata L (2021) Changes in Glycolytic Pathway in SARS-COV 2 Infection and Their Importance in Understanding the Severity of COVID-19. Front. Chem. 9:685196. doi: 10.3389/fchem.2021.685196pt_PT
dc.identifier.doi10.3389/fchem.2021.685196pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.6/12305
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherFrontiers Media SApt_PT
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fchem.2021.685196/fullpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectGlycolytic pathwaypt_PT
dc.subjectCOVID-19pt_PT
dc.subjectOxidative phosphorylationpt_PT
dc.subjectReactive oxygen speciespt_PT
dc.subjectHyperglycolysispt_PT
dc.titleChanges in Glycolytic Pathway in SARS-COV 2 Infection and Their Importance in Understanding the Severity of COVID-19pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue685196pt_PT
oaire.citation.titleFrontiers in Chemistrypt_PT
oaire.citation.volume9pt_PT
person.familyNameDos Santos
person.familyNameSarmento Rodrigues Povoa
person.familyNamePereira Cruz Paixão
person.familyNameMendonça
person.familyNameTaborda Barata
person.givenNameAdalberto Fernandes Pereira
person.givenNamePedro Manuel
person.givenNamePaulo Jorge
person.givenNameAntónio
person.givenNameLuis
person.identifier104007
person.identifier.ciencia-id5110-22E2-6E6B
person.identifier.ciencia-id0C16-5CF9-9238
person.identifier.ciencia-idB91C-2824-F232
person.identifier.ciencia-id2419-6E20-F958
person.identifier.ciencia-id1E1F-8A43-055B
person.identifier.orcid0000-0001-7797-192X
person.identifier.orcid0000-0002-7069-7304
person.identifier.orcid0000-0001-8069-0440
person.identifier.orcid0000-0001-6649-8890
person.identifier.ridI-3093-2012
person.identifier.scopus-author-id56890866600
person.identifier.scopus-author-id15128160500
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication4600e721-d143-404f-9e78-48216c534097
relation.isAuthorOfPublication876ed64e-53ad-4f72-b677-bfc62f2b5bb8
relation.isAuthorOfPublicationcaaad4dd-f359-4e74-bfe9-c95223ba32ad
relation.isAuthorOfPublicationfbccceb8-2850-4fe1-ae4f-4aeded7bf32a
relation.isAuthorOfPublication3f1ad371-56e3-4fda-9409-748e355a0de1
relation.isAuthorOfPublication.latestForDiscovery876ed64e-53ad-4f72-b677-bfc62f2b5bb8

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
2021 Santos fC.pdf
Size:
1.1 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: